NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) and Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Profitability
This table compares NRx Pharmaceuticals and Lexaria Bioscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NRx Pharmaceuticals | N/A | N/A | -449.16% |
| Lexaria Bioscience | -1,249.14% | -86.10% | -80.32% |
Institutional and Insider Ownership
4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 19.0% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NRx Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
| Lexaria Bioscience | 0 | 0 | 2 | 0 | 3.00 |
NRx Pharmaceuticals presently has a consensus price target of $31.67, suggesting a potential upside of 1,077.20%. Lexaria Bioscience has a consensus price target of $11.00, suggesting a potential upside of 380.35%. Given NRx Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts plainly believe NRx Pharmaceuticals is more favorable than Lexaria Bioscience.
Volatility and Risk
NRx Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
Earnings & Valuation
This table compares NRx Pharmaceuticals and Lexaria Bioscience”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NRx Pharmaceuticals | N/A | N/A | -$30.15 million | ($2.14) | -1.26 |
| Lexaria Bioscience | $464,278.00 | 86.08 | -$5.80 million | ($0.47) | -4.87 |
Lexaria Bioscience has higher revenue and earnings than NRx Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
NRx Pharmaceuticals beats Lexaria Bioscience on 8 of the 14 factors compared between the two stocks.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
